In the latest session, Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) closed at $18.85 down -1.52% from its previous closing price of $19.14. On the day, 1220561 shares were traded. AMLX stock price reached its highest trading level at $19.41 during the session, while it also had its lowest trading level at $18.40.
Ratios:
For a deeper understanding of Amylyx Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.44 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 119.51. For the most recent quarter (mrq), Quick Ratio is recorded 5.20 and its Current Ratio is at 5.66. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on January 03, 2024, initiated with a Outperform rating and assigned the stock a target price of $37.
On December 12, 2023, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $36.
Goldman Upgraded its Neutral to Buy on July 24, 2023, whereas the target price for the stock was revised from $45 to $49.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 23 when Mazzariello Gina sold 2,838 shares for $18.76 per share. The transaction valued at 53,231 led to the insider holds 46,245 shares of the business.
Klee Justin B. sold 5,841 shares of AMLX for $95,372 on Jan 09. The Co-Chief Executive Officer now owns 2,836,776 shares after completing the transaction at $16.33 per share. On Jan 09, another insider, Cohen Joshua B, who serves as the Co-Chief Executive Officer of the company, sold 5,841 shares for $16.33 each. As a result, the insider received 95,372 and left with 2,900,470 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMLX now has a Market Capitalization of 1.28B and an Enterprise Value of 910.57M. As of this moment, Amylyx’s Price-to-Earnings (P/E) ratio for their current fiscal year is 26.74, and their Forward P/E ratio for the next fiscal year is 12.17. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.35 while its Price-to-Book (P/B) ratio in mrq is 2.94. Its current Enterprise Value per Revenue stands at 2.39 whereas that against EBITDA is 22.83.
Stock Price History:
Over the past 52 weeks, AMLX has reached a high of $38.32, while it has fallen to a 52-week low of $11.82. The 50-Day Moving Average of the stock is 15.91, while the 200-Day Moving Average is calculated to be 18.82.
Shares Statistics:
For the past three months, AMLX has traded an average of 1.24M shares per day and 2.01M over the past ten days. A total of 67.71M shares are outstanding, with a floating share count of 51.63M. Insiders hold about 23.74% of the company’s shares, while institutions hold 89.52% stake in the company. Shares short for AMLX as of Feb 15, 2024 were 4.98M with a Short Ratio of 4.01, compared to 5.73M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 7.35% and a Short% of Float of 9.78%.
Earnings Estimates
There are 5 different market analysts currently analyzing its stock. On average, analysts expect EPS of $0.15 for the current quarter, with a high estimate of $0.3 and a low estimate of $0.06, while EPS last year was $0.02. The consensus estimate for the next quarter is $0.22, with high estimates of $0.4 and low estimates of $0.08.
Analysts are recommending an EPS of between $2.13 and $0.36 for the fiscal current year, implying an average EPS of $1. EPS for the following year is $1.55, with 7 analysts recommending between $3.32 and $0.63.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $112.57M this quarter.It ranges from a high estimate of $114.86M to a low estimate of $109.2M. As of the current estimate, Amylyx Pharmaceuticals Inc’s year-ago sales were $71.43M, an estimated increase of 57.60% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $119.99M, an increase of 22.20% less than the figure of $57.60% in the same quarter last year. There is a high estimate of $122.69M for the next quarter, whereas the lowest estimate is $114.4M.
A total of 7 analysts have provided revenue estimates for AMLX’s current fiscal year. The highest revenue estimate was $499.7M, while the lowest revenue estimate was $448.4M, resulting in an average revenue estimate of $483.1M. In the same quarter a year ago, actual revenue was $380.79M, up 26.90% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $579.29M in the next fiscal year. The high estimate is $713.33M and the low estimate is $520.26M. The average revenue growth estimate for next year is up 19.90% from the average revenue estimate for this year.
